

Provided by:



## Hematology Oncology Fellows Tumor Board Case Conference 2023-2024

**Hematology Oncology Fellows Tumor Board Case Conference 2023-2024 - 4/6/2023**

**April 6, 2023**

**8:00 AM - 9:00 AM**

**12-122 Perelman Center South Pavilion**

### **Target Audience**

This program has been designed for Internal Medicine - Hematology, Internal Medicine - Medical Oncology

### **Series Educational Objectives**

After participating in this regularly scheduled series, participants should be able to:

- 1 Describe how to improve knowledge and skills related to treatment options for patients with cancer
- 2 Discuss how to improve knowledge and skills related to making proper evaluation, and as a consultant for patients with unknown diagnosis, but with possible malignancy
- 3 Describe the role of the medical oncologist in managing patient cancer

### **Accreditation**

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

### **Designation of Credit**

**Physicians:** Penn Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Nurses:** This activity is not approved for nursing contact hours

**Pharmacists:** This activity is not approved for pharmacy contact hours

**PAs:** AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit*<sup>™</sup> from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of **1.00** Category 1 credits for completing this activity.

**Approved for (PSRM) patient safety/risk management designation**

### **Acknowledgement of Commercial Support\***

None

For more information, please contact  
Alexa Davis  
(215) 662-3681  
alexandra.davis@uphs.upenn.edu

**Check your transcript online at <https://upenn.cloud-cme.com>**

### Disclosure of Relevant Financial Relationships and Unapproved Uses of Products

It is policy at Penn Medicine Office of Continuing Medical and Interprofessional Education for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships (RFRs) that they have with any ineligible company, which is defined as any company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Disclosure to learners includes all RFRs for all those in control of content including faculty, planners, moderators, and reviewers.

The intent of this policy is to ensure that Penn CME/CE certified activities promote quality and safety, are effective in improving medical practice, are evidence-based on valid content, and are independent of control from ineligible companies and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information was found to contain any financial relationships. Part of the peer review process involved reviewing the content, determining which financial relationships were relevant and, applying appropriate mitigation strategies. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.

The staff in the Office of Continuing Medical and Interprofessional Education (CME and IPCE), have disclosed that they have no relevant financial relationships with any ineligible companies. Any peer reviewer who is determined to have a relevant financial relationship must recuse themselves from the peer review process.

Name of individual	Individual's role in activity	Name of Ineligible Company(s) / Nature of Relationship(s)
Sunita D. Nasta, MD, FACP	Co-Director	Grant or research support-Genentech   Grant or research support-Takeda Pharmaceuticals   Grant or research support-AbbVie, Inc.   Membership on Advisory Committees or Review Panels, Board Membership, etc.-Merck & Co - 12/16/2022
Ursina Teitelbaum, MD	Co-Director	Nothing to disclose - 12/11/2022
Erin Aakhus, MD	Course Director	Nothing to disclose - 09/07/2022
Minh Than, MD, PhD	Faculty, Other Planning Committee Member	Nothing to disclose - 07/18/2022
Sriram Anbil, MD	Other Planning Committee Member	Nothing to disclose - 07/19/2022
Mathew Angelos, MD, PhD	Other Planning Committee Member	Nothing to disclose - 10/27/2022
Rahul S Bhansali, MD	Other Planning Committee Member	Nothing to disclose - 01/11/2023
Timothy J Brown, MD	Other Planning Committee Member	Nothing to disclose - 10/19/2022
David Cantor, MD, PhD	Other Planning Committee Member	Nothing to disclose - 01/11/2023
Bryan T Ciccarelli, MA	Other Planning Committee Member	Nothing to disclose - 02/06/2023

Matthew Connor, MD	Other Planning Committee Member	Nothing to disclose - 06/28/2022
Mia Djulbegovic, MD	Other Planning Committee Member	Nothing to disclose - 07/13/2022
Putzer Hung, MD, PhD	Other Planning Committee Member	Nothing to disclose - 07/22/2022
Benjamin Manning, MD, PhD	Other Planning Committee Member	Nothing to disclose - 09/09/2022
Patrick Mellors, MD	Other Planning Committee Member	Nothing to disclose - 03/03/2023
Debanjan Pain, MD	Other Planning Committee Member	Nothing to disclose - 07/07/2022
Beatrice Razzo, MD	Other Planning Committee Member	Nothing to disclose - 07/13/2022
Christopher T Sauter, MD	Other Planning Committee Member	Nothing to disclose - 07/13/2022
Michael Schneider, MD, PhD	Other Planning Committee Member	Nothing to disclose - 07/19/2022
Robert Schwab, MD	Other Planning Committee Member	Nothing to disclose - 04/29/2022
Jeffrey Shevach, MD	Other Planning Committee Member	Honoraria-MJH Life Sciences (Relationship has ended) Other: Travel Fees-DAVA Oncology (Relationship has ended) - 01/11/2023
Eleanor Taranto, MD	Other Planning Committee Member	Nothing to disclose - 07/11/2022
Montreh Tavakkoli, MD, MA	Other Planning Committee Member	Nothing to disclose - 09/08/2022
Elizabeth Traxler, MD, PhD	Other Planning Committee Member	Nothing to disclose - 10/25/2022
Shannon Ugarte, MD	Other Planning Committee Member	Nothing to disclose - 07/07/2022
Xin Wang, MD	Other Planning Committee Member	Nothing to disclose - 07/14/2022
Emmett Wynter, MD	Other Planning Committee Member	Nothing to disclose - 11/22/2022

All relevant financial relationships have been mitigated.

Relevant financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit where the business lines of the ineligible company relate to the content of the activity. Financial interests are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected.